
AwardNov 19, 2026, 06:52 PM
Mesoblast Wins Deloitte Technology Fast 50 Leadership Award
AI Summary
Mesoblast Limited has been honored with the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards. This award recognizes the company's significant growth and its successful transition to a commercial-stage biotechnology firm, highlighted by the U.S. launch of Ryoncil® (remestemcel-L-rknd). Mesoblast's CEO, Dr. Silviu Itescu, expressed pleasure in receiving the award, emphasizing the company's innovation, scalability, and the positive impact of Ryoncil® on patients. The company is focused on expanding its portfolio and delivering long-term shareholder value.
Key Highlights
- Mesoblast Limited received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards.
- The award acknowledges Mesoblast's evolution into a commercial-stage biotechnology company.
- This recognition follows the U.S. launch of Ryoncil® (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell therapy.
- Mesoblast is a global leader in developing allogeneic cellular medicines for inflammatory diseases.
- The company has a strong intellectual property portfolio with over 1,000 granted patents or applications extending protection to at least 2044.
Price Impact
More from MESO